|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that the fusion of FIP1L1 to PDGFRA occurs rarely in leukemia cell lines, but they identify EOL-1 as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and for the analysis of small molecule inhibitors of FIP1L1-PDGFRalpha.
|
14630792 |
2004 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vitro and in vivo studies confirmed that FIP1L1-PDGFRalpha is a therapeutic target of imatinib, forming a rational basis for the treatment of FIP1L1-PDGFRA positive chronic eosinophilic leukemia and mastocytosis with imatinib.
|
14676627 |
2004 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, correlating IHES/CEL genotype with phenotype, FIP1L1-PDGFRA (+) CEL emerges as a homogeneous clinicobiological entity, where imatinib can induce molecular remission.
|
14973504 |
2004 |
|
Chronic eosinophilic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The discovery of the FIP1L1-PDGFRA fusion gene has led to the recognition that many patients who would previously have been regarded as having idiopathic hypereosinophilia actually have chronic eosinophilic leukemia.
|
15307112 |
2004 |
|
Chronic eosinophilic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increased bone marrow blasts (>5%) or cytogenetic/genetic markers indicate chronic eosinophilic leukemia (CEL).A cryptic deletion of 4q12, i.e. del(4)(q12), producing the FIP1L1/PDGFRA fusion gene, identifies a distinct CEL subgroup (4q-/CEL).
|
15921374 |
2005 |
|
Chronic eosinophilic leukemia
|
0.400 |
FusionGene
|
disease |
ORPHANET |
We recently identified the FIP1L1-PDGFRA fusion gene in approx 50% of HES/CEL cases.
|
16502585 |
2006 |
|
Chronic eosinophilic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that low doses of sorafenib could be efficient for the treatment of FIP1L1-PDGFRA-positive CEL and could be used to overcome resistance to imatinib associated with the T674I mutation.
|
16645167 |
2006 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Splenomegaly was constant in FIP1L1-PDGFRA positive CEL but not in the other HES patients (only 1/3).
|
17137731 |
2007 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fluorescence in situ hybridization specific for BCR-ABL1 and for FIP1L1-PDGFRA was combined with cytomorphology or with lineage-restricted monoclonal antibodies and applied in CML and CEL, respectively.
|
17215855 |
2007 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
|
17299092 |
2007 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.
|
17555450 |
2007 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
As targeted therapy with tyrosine kinase inhibitors has dramatically changed the prognosis of FIP1L1-PDGFRA (+) CEL, false-negative results could hamper accurate diagnosis and treatment.
|
17591942 |
2007 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This system correctly classified 16 of 17 FIP1L1/PDGFRA-positive patients with CEL and all 12 patients with systemic mastocytosis with eosinophilia.
|
17628645 |
2007 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data are consistent with suppression rather than elimination of the clonal population in FIP1L1/PDGFRA-positive CEL and suggest that molecular monitoring may be the most useful method in determining optimal dosing without the risk of disease exacerbation.
|
17709602 |
2007 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We genotyped six single-nucleotide polymorphisms (SNP) within or close to the IL5RA or IL5 genes in 82 patients with FIP1L1-PDGFRA-positive CEL plus, as controls, healthy individuals (n=100), patients with FIP1L1-PDGFRA-negative eosinophilia (n=100) or patients with chronic myeloid leukaemia (CML) (n=100).
|
17914408 |
2007 |
|
Chronic eosinophilic leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After 2001, the detection of the high frequency of the JAK2V617F mutation in PV, CIMF, and ET, and of the FIP1L1-PDGFRA fusion gene in CEL further added important information in the diagnosis of CMPD.
|
17938925 |
2008 |
|
Chronic eosinophilic leukemia
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Thus, imatinib may be very effective for treating the early cardiac involvement of FIP1L1-PDGFRA-positive CEL, but it needs to be used cautiously.
|
17988989 |
2007 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, imatinib may be very effective for treating the early cardiac involvement of FIP1L1-PDGFRA-positive CEL, but it needs to be used cautiously.
|
17988989 |
2007 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, a recent report noted two cases with the association of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma (T-LBL).
|
18028420 |
2008 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
|
18256119 |
2008 |
|
Chronic eosinophilic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The identification of novel drug-resistant FIP1L1-PDGFRA variants may help to develop the next generation of target-directed compounds for CEL/HES and other leukemias.
|
19210352 |
2009 |
|
Chronic eosinophilic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Chronic eosinophilic leukemia (CEL) is a rare myeloproliferative neoplasm characterized by the FIP1L1-PDGFRA fusion gene, variant PDGFRA fusions or other genetic lesions.
|
19212337 |
2009 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
As such, the fusion gene FIP1L1/PDGFRA was found as a cause of CEL in a significant proportion of patients initially diagnosed as having HES.
|
19494514 |
2009 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this paper, we screened 77 patients to estimate the frequency of FIP1L1-PDGFRA transcript among patients with unexplained, long-term hypereosinophilia exceeding 1.5 x 10(9)/L and to analyse the clinical and serological features in F/P+ CEL population.
|
19728396 |
2010 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic myeloid neoplasm with eosinophilia and abnormalities of platelet-derived growth factor receptor alpha (PDGFRA), referred to until 2008 as chronic eosinophilic leukemia, is distinguished from hypereosinophilic syndrome (HES), if accompanied by genetic abnormalities that enable to determine eosinophil clonality.
|
20010473 |
2009 |